

### Company Overview

Emerald Bioscience Inc. is a biopharmaceutical company focused on the discovery and development of first-in-class molecules with strong clinical and commercial differentiation for conditions with significant, global, unmet medical needs. With proprietary technology licensed from the University of Mississippi, the Company is developing novel ways to deliver its synthetic cannabinoid-derived molecules for specific indications with the aim of optimizing therapeutic benefit. The Company's aim is to clinically develop multiple proprietary compounds alone or in combination with corporate partners.

### Emerald Bioscience to Present at the KCSA Cannabis Investor Conference

Jan 5 2021, 8:30 AM EST

### Emerald Bioscience Reports that Superior Reduction of Intraocular Pressure of its Unique Nanoemulsion Formulation of THCvHS is Published in Peer-Reviewed Journal

Dec 16 2020, 8:30 AM EST

### Emerald Bioscience to Present at the Benzinga Global Small Cap Virtual Conference

Dec 7 2020, 8:44 AM EST

### Stock Overview

Symbol	EMBI
Exchange	OTCQB
Market Cap	22.13m
Last Price	\$0.08
52-Week Range	\$0.03 - \$0.21

01/14/2021 03:59 PM EST

### Investor Relations

EMBI Investor Relations  
T: 949-396-0330  
[invest@emeraldbio.life](mailto:invest@emeraldbio.life)

### Management Team

#### Punit Dhillon

Chief Executive Officer and Executive Chairman

#### Dennis Kim, MD, MBA

Chief Medical Officer

#### Alice Chen

Executive Director, Clinical Operations

#### Richard Janney

Interim Principal Accounting Officer

### Emerald Bioscience, Inc.

5910 Pacific Center Blvd.  
Suite 320  
San Diego, CA 92121

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.